| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/23/2003 | EP0975636B1 1h-pyrazolo[3,4-d]pyrimidine-4,6-diones as t-cell proliferation inhibitors |
| 07/23/2003 | EP0969849B1 Stable solid preparation containing vitamin d3 and tricalcium phosphate |
| 07/23/2003 | EP0961613A4 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis |
| 07/23/2003 | EP0930831B1 Flavonol containing food supplements |
| 07/23/2003 | EP0929528B1 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 07/23/2003 | EP0898559B1 Cytoprotective compounds |
| 07/23/2003 | EP0820290B1 Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism |
| 07/23/2003 | EP0814827B1 Vascular endothelial growth factor-b |
| 07/23/2003 | EP0811011B1 Carbohydrate conjugated bio-active compounds |
| 07/23/2003 | EP0714408B1 Tryptase inhibitor |
| 07/23/2003 | EP0628033B1 Benzodiazepin derivatives useful as cck-receptor antagonists |
| 07/23/2003 | CN1432022A Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| 07/23/2003 | CN1432020A 嘌呤衍生物 Purine derivatives |
| 07/23/2003 | CN1432015A Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
| 07/23/2003 | CN1432013A Imidazole derivatives or salts thereof and drugs contg. derivatives or salts |
| 07/23/2003 | CN1432012A Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for treatment of pain |
| 07/23/2003 | CN1432011A Benzoamide piperidine compounds as substance P antagonists |
| 07/23/2003 | CN1432004A Alkynyl phenyl heteroaromatic glucokinase activators |
| 07/23/2003 | CN1432000A TNF-alpha prodn. inhibitors |
| 07/23/2003 | CN1431999A Indole derivatives with vascular damagine activity |
| 07/23/2003 | CN1431997A 2-acyl indol derivatives and their use as anti-tumour agents |
| 07/23/2003 | CN1431995A Antipicornaviral compounds and compsns. their pharmaceutical uses, and materials for their synthesis |
| 07/23/2003 | CN1431912A Combination product comprising melagatran and factor Xa inhibitor |
| 07/23/2003 | CN1431907A Method of treating hepatitis delta viral infection |
| 07/23/2003 | CN1431905A Use of fulvestrant in treatment of resistant breast cancer |
| 07/23/2003 | CN1431904A Protease inhitors |
| 07/23/2003 | CN1431902A Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 07/23/2003 | CN1431899A Pharmaceutical combination of bicalutamide and tamoxifen for providing anti-androgenic effect and anti-oestrogenic effect |
| 07/23/2003 | CN1431898A Methods of use of penicillamines for treatment of conditions resulting from DNA damage |
| 07/23/2003 | CN1431017A Microcapsule meterial for durative releasing two factors for restraining new-born blood vessels and its preparing method |
| 07/23/2003 | CN1430978A Astragalus cream of female use and its preparing method |
| 07/23/2003 | CN1430977A Capsule sheep extractive for protecting, strengthening health and preserving youth |
| 07/23/2003 | CN1115342C Hypnotic beta-carboline derivatives, process for their prepn. and their use as medicinal products |
| 07/23/2003 | CN1115341C Substituted N-methyl-N-(4-(1H-benzimidazol-2-yl-amino) piperidin-1-yl)-2-(aryl) butyl) benzamides useful for treatment of allergic diseases |
| 07/23/2003 | CN1115334C Pyridine derivative and pharmaceutical contg. same |
| 07/23/2003 | CN1115330C N-(4-carbamimido-phenyl)-phenylglycinamid derivatives |
| 07/23/2003 | CN1115163C Health-care product for removing toxic material and delaying senility and its prepn. method |
| 07/22/2003 | USRE38200 Indole-2,3-dione-3-oxime derivatives |
| 07/22/2003 | US6596900 Brain, nervous system, neurodegenerative, gastrointestinal, sleep, rheumatic, and psychological disorders; analgesics, antiepileptic agents |
| 07/22/2003 | US6596874 Salt formation by reaction using benzenesulfonic acid |
| 07/22/2003 | US6596772 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are |
| 07/22/2003 | US6596761 Cosmetic and dermatological preparation with flavonoids |
| 07/22/2003 | US6596757 Taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more polyethylene glycol-containing taxanes covalently bonded to a cell binding |
| 07/22/2003 | US6596754 Preventives/remedies for multiple organ failure |
| 07/22/2003 | US6596753 Compounds of the indolecarboxylic family and use thereof |
| 07/22/2003 | US6596751 α-substituted carboxylic acid derivatives |
| 07/22/2003 | US6596749 Neuropeptide y receptor ligand |
| 07/22/2003 | US6596746 Cyclic protein tyrosine kinase inhibitors |
| 07/22/2003 | US6596742 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use in medicaments |
| 07/22/2003 | US6596738 Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): |
| 07/22/2003 | US6596735 Compounds and to the use of said compounds for inhibiting abnormal cell growth in mammals. The compounds of the above formula have activity as farnesyl protein transferase inhibitors. for treatment of cancer andhyperproliferation |
| 07/22/2003 | US6596731 Substituted imidazo[1,2-A] pyridine derivatives |
| 07/22/2003 | US6596730 Phenyl urea and phenyl thiourea derivatives |
| 07/22/2003 | US6596729 Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
| 07/22/2003 | US6596726 Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme |
| 07/22/2003 | US6596722 Serotonin reuptake inhibitors/HT3 receptor antagonists useful for treatment of depression, psychosis, anxiety disorders, panic disorder, obsessive compulsive disorder, and eating disorders |
| 07/22/2003 | US6596721 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 07/22/2003 | US6596720 Potentiating an anti-HIV activity of trifluridine and derivatives in thereof in a mammal, including human, comprising administering to said mammal, including human, an effective amount of a thymidine phosphorylase inhibitor and |
| 07/22/2003 | US6596715 Protease inhibitors |
| 07/22/2003 | US6596711 GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux |
| 07/22/2003 | US6596701 S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| 07/22/2003 | US6596698 Localized arterial transduction of RB2/pl30 via a viral vector at the time of angioplasty drastically reduces neointimal hyperplasia and prevents restenosis |
| 07/22/2003 | US6596696 Alpha-amylase inhibitor for the prophylaxis and treatment of hyperglycemia |
| 07/22/2003 | US6596687 Cell adhesion inhibitors |
| 07/22/2003 | US6596533 Polypeptide for use in the treatment of infections and cell proliferative disorders |
| 07/22/2003 | US6596518 Culture product; lipase inhibitor |
| 07/22/2003 | US6596515 Insulin gene amplified from human genomic DNA by use of a pair of insulin primers and a K14 promoter gene amplified by use of a pair of K14 primers inserted together into pUChsneo |
| 07/22/2003 | US6596498 Bone stimulating factor |
| 07/22/2003 | US6596301 Lactobacillus helveticus fermented sour milk; ameliorating tension, depression fatigue and emotional derangement |
| 07/22/2003 | US6596270 Administering the adenoviral gene transfer vector (exogenous) encoding a gene product to a muscle and the vector is neutralized outside of the muscle by systemic neutralizing antibodies; using a chimeric coat protein for cell entry |
| 07/22/2003 | US6596268 Viruses for the treatment of cellular proliferative disorders |
| 07/22/2003 | CA2198833C Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans |
| 07/22/2003 | CA2109320C Peptide nucleic acids |
| 07/21/2003 | CA2416791A1 A receptor-ligand pairing for immune response |
| 07/21/2003 | CA2368656A1 Receptor-ligand pairing for anti-inflammatory response |
| 07/17/2003 | WO2003057919A2 The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
| 07/17/2003 | WO2003057912A2 Molecular trichogram |
| 07/17/2003 | WO2003057888A1 Cell-specific expression/replication vector |
| 07/17/2003 | WO2003057880A1 Method of quantifying nucleic acid and kit for quantifying nucleic acid |
| 07/17/2003 | WO2003057878A1 INDUCTION OF THE FORMATION OF INSULIN-PRODUCING CELLS VIA GENE TRANSFER OF PANCREATIC β-CELL-ASSOCIATED TRANSCRIPTIONAL FACTOR |
| 07/17/2003 | WO2003057837A2 Methods for using anti-muc18 antibodies |
| 07/17/2003 | WO2003057835A2 Pak5-related compositions and methods |
| 07/17/2003 | WO2003057826A2 SOLUBLE GLcNAC PHOSPHOTRANSFERASE |
| 07/17/2003 | WO2003057730A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | WO2003057729A2 Mammal prolactin variants |
| 07/17/2003 | WO2003057725A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 07/17/2003 | WO2003057722A2 Cyclic tetrapeptide compound and use thereof |
| 07/17/2003 | WO2003057707A1 2-o-( -d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 07/17/2003 | WO2003057699A1 Dibenzodiazepine derivates, their preparation and use |
| 07/17/2003 | WO2003057698A2 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/17/2003 | WO2003057696A1 Deazapurines and uses thereof |
| 07/17/2003 | WO2003057693A1 5-membered cyclic compounds |
| 07/17/2003 | WO2003057692A1 Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof |
| 07/17/2003 | WO2003057691A1 Process and intermediates for pyridazinone antidiabetic agents |
| 07/17/2003 | WO2003057690A1 Indolinone derivatives useful as protein kinase inhibitors |
| 07/17/2003 | WO2003057688A2 Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators |
| 07/17/2003 | WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | WO2003057674A1 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | WO2003057673A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | WO2003057672A2 Tetrahydroquinoline analogues as muscarinic agonists |